Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Trastuzumab deruxtecan versus standard therapy for molecular relapse in early breast cancer

Phase 3 randomized trial of trastuzumab deruxtecan versus standard therapy after molecular relapse. The registry primary outcome is the ctDNA clearance rate 12 months after randomization. ClinicalTrials.gov lists the study as recruiting.

Prof. Wolfgang Janni